Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages
- PMID: 21831565
- PMCID: PMC3225636
- DOI: 10.1016/j.jsat.2011.06.009
Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages
Abstract
Identifying facilitators of more rapid buprenorphine adoption may increase access to this effective treatment for opioid dependence. Using a diffusion of innovations theoretical framework, we examine the extent to which programs' interorganizational institutional and resource-based linkages predict the likelihood of being an earlier adopter, later adopter, or nonadopter of buprenorphine. Data were derived from face-to-face interviews with administrators of 345 privately funded substance abuse treatment programs in 2007-2008. Results of multinomial logistic regression models show that interorganizational and resource linkages were associated with timing of adoption. Programs reporting membership in provider associations were more likely to be earlier adopters of buprenorphine. Programs that relied more on resource linkages, such as detailing activities by pharmaceutical companies and the National Institute on Drug Abuse website, were more likely to be earlier adopters of buprenorphine. These findings suggest that institutional and resource-based interorganizational linkages may expose programs to effective treatments, thereby facilitating more rapid and sustained adoption of innovative treatment techniques.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.Med Care Res Rev. 2014 Feb;71(1):43-60. doi: 10.1177/1077558713503188. Epub 2013 Sep 18. Med Care Res Rev. 2014. PMID: 24051897 Free PMC article.
-
Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.J Subst Abuse Treat. 2006 Jun;30(4):363-73. doi: 10.1016/j.jsat.2006.03.013. J Subst Abuse Treat. 2006. PMID: 16716852
-
Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.J Behav Health Serv Res. 2010 Jul;37(3):322-37. doi: 10.1007/s11414-009-9169-z. Epub 2009 Mar 19. J Behav Health Serv Res. 2010. PMID: 19296223 Free PMC article.
-
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Rural Remote Health. 2015. PMID: 25651434 Review.
-
Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.Adv Anesth. 2019 Dec;37:65-86. doi: 10.1016/j.aan.2019.08.002. Epub 2019 Sep 27. Adv Anesth. 2019. PMID: 31677660 Review. No abstract available.
Cited by
-
Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC Health Serv Res. 2021 Nov 5;21(1):1198. doi: 10.1186/s12913-021-07196-4. BMC Health Serv Res. 2021. PMID: 34740338 Free PMC article.
-
Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.Drug Alcohol Depend. 2016 Apr 1;161:214-21. doi: 10.1016/j.drugalcdep.2016.02.007. Epub 2016 Feb 10. Drug Alcohol Depend. 2016. PMID: 26898185 Free PMC article.
-
Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.Drug Alcohol Depend. 2016 Mar 1;160:112-8. doi: 10.1016/j.drugalcdep.2015.12.031. Epub 2016 Jan 6. Drug Alcohol Depend. 2016. PMID: 26796596 Free PMC article.
-
Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers.J Behav Health Serv Res. 2016 Jul;43(3):354-65. doi: 10.1007/s11414-015-9466-7. J Behav Health Serv Res. 2016. PMID: 25934355 Free PMC article.
-
Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.J Subst Abuse Treat. 2015 Jan;48(1):112-6. doi: 10.1016/j.jsat.2014.07.015. Epub 2014 Aug 7. J Subst Abuse Treat. 2015. PMID: 25205666 Free PMC article.
References
-
- Alkhateeb FM, Khanfar NM, Clauson KA. Characteristics of Physicians Who Frequently See Pharmaceutical Sales Representatives. Journal of Hospital Marketing & Public Relations. 2009;19(1):2–14. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01DA013110/DA/NIDA NIH HHS/United States
- R01DA14482/DA/NIDA NIH HHS/United States
- R37 DA013110/DA/NIDA NIH HHS/United States
- R01 AA015974/AA/NIAAA NIH HHS/United States
- F32 AA016872/AA/NIAAA NIH HHS/United States
- R01 DA013110/DA/NIDA NIH HHS/United States
- R01 DA013110-10/DA/NIDA NIH HHS/United States
- R01 DA014482-10/DA/NIDA NIH HHS/United States
- F32 AA016872-03/AA/NIAAA NIH HHS/United States
- R01 DA014482/DA/NIDA NIH HHS/United States
- R01 AA015974-05/AA/NIAAA NIH HHS/United States
- R01AA015974/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical